Immuneering announces its inclusion in the Russell 2000® Index

CAMBRIDGE, Mass., September 20, 2021 (GLOBE NEWSWIRE) – Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company developing a strong pipeline of oncology and neuroscience product candidates designed to uniquely disrupt the dynamics of cell signaling, announced today that Immuneering Corporation has been selected for addition to the Russell 2000® Index effective September 20, 2021, after the close of US stock markets.

“We are delighted to have been selected for inclusion in the Russell 2000® Index. Our investment in this widely used performance benchmark for small-cap companies reflects the success of our recent IPO and our progress towards drugs targeting cancers caused by alterations that activate the RAS / MAPK pathway. With our inclusion in the Russell 2000®, we look forward to increased exposure to the investment community and other key stakeholders with our history, ”said Ben Zeskind, Ph.D., co-founder, president and CEO of Immuneering.

The Russell 2000® Index measures the performance of the small cap segment of the US stock market. The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of this index. It includes around 2,000 of the smaller stocks based on a combination of their market capitalization and their current index membership.

Russell Indices are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $ 9 trillion in assets is compared to the US Russell Indices which are part of FTSE Russell, a global index leader that provides innovative benchmarking, analysis and data solutions to investors around the world.

For more information on the Russell Indices, please visit the FTS Russell website at

About Immuneering Corporation
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes in a range of debilitating oncologic and neurologic diseases by applying its in-depth knowledge of translational bioinformatics at every stage of the drug development process. Immuneering has over a decade of experience in translational bioinformatics and in generating information on the mechanisms of drug action and responses to treatment of patients. Building on this experience, Immuneering has developed a disease independent platform that enables the company to use human data, novel biology and chemistry, and translational planning to create and advance its owned pipeline. exclusive. Immuneering’s current development programs in oncology focus on providing potential treatments for patients with solid tumors caused by mutations in oncological signaling pathways, including the MAPK pathway. Immuneering’s flagship product candidate, IMM-1-104, is designed to be a highly selective dual MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients with RAS mutant tumors. In addition, Immuneering has six other discovery-stage oncology programs that are designed to target the MAPK or mTOR pathway, and two discovery-stage neuroscience programs.

Forward-looking statements

This press release includes certain disclosures that contain “forward-looking statements” including, without limitation, statements regarding Immuneering’s progress towards drugs targeting cancers caused by alterations that activate the RAS / MAPK pathway and increased market exposure resulting from inclusion in the Russell 2000 ® Index. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions which are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in drug development in oncology and neuroscience, including target discovery, target validation, lead compound identification , optimization of flagship compounds, preclinical studies and clinical trials. These and other risks and uncertainties are further described in the section entitled “Risk Factors” in the Company’s most recent Form 10-Q filed with the State Securities and Exchange Commission (SEC). United as well as in subsequent Immuneering filings it makes with the SEC. . The forward-looking statements contained in this announcement are made as of this date and Immuneering does not undertake to update this information, except as required by applicable law.

Corporate contact:
Rebecca Kusko, Ph.D.
Immunization company
[email protected]

Investor contact:
Anne-Marie Champs
General manager
Rx communications
[email protected]

Previous Governor Abbott Calls on President Biden for Federal Declaration of Emergency for State of Texas in Response to Border Crisis | Texas Governor's Office
Next Saint Angela of Europe? - The Globalist

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *